Literature DB >> 9573260

Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes.

E Konishi1, M Yamaoka, I Kurane, P W Mason.   

Abstract

A DNA vaccine plasmid containing the Japanese encephalitis (JE) virus premembrane (prM) and envelope (E) genes (designated pcDNA3JEME) was evaluated for immunogenicity and protective efficacy in mice. Two immunizations of 4-week-old female ICR mice with pcDNA3JEME by intramuscular or intradermal injections at a dose of 10 or 100 microg per mouse elicited neutralizing (NEUT) antibodies at titers of 1:10 to 1:20 (90% plaque reduction), and all immunized mice survived a challenge with 10,000 50% lethal doses of the P3 strain of JE virus. A single immunization with 100 microg of pcDNA3JEME did not elicit detectable NEUT antibodies but induced protective immunity. Spleen cells obtained from BALB/c mice immunized once with 10 or 100 microg of pcDNA3JEME contained JE virus-specific memory cytotoxic T lymphocytes (CTLs). BALB/c mice maintained detectable levels of memory B cells and CTLs for at least 6 months after one immunization with pcDNA3JEME at a dose of 100 microg. The CTLs induced in BALB/c mice immunized twice with 100 microg of pcDNA3JEME were CD8 positive and recognized mainly the envelope protein. These results indicate that pcDNA3JEME has the ability to induce a protective immune response which includes JE virus-specific antibodies and CTLs.

Entities:  

Mesh:

Year:  1998        PMID: 9573260      PMCID: PMC110053          DOI: 10.1128/JVI.72.6.4925-4930.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection.

Authors:  B M Kaufman; P L Summers; D R Dubois; W H Cohen; M K Gentry; R L Timchak; D S Burke; K H Eckels
Journal:  Am J Trop Med Hyg       Date:  1989-11       Impact factor: 2.345

2.  Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies.

Authors:  J Kimura-Kuroda; K Yasui
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

3.  Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus.

Authors:  E A Henchal; L S Henchal; J J Schlesinger
Journal:  J Gen Virol       Date:  1988-08       Impact factor: 3.891

4.  Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.

Authors:  E L Cooney; A C Collier; P D Greenberg; R W Coombs; J Zarling; D E Arditti; M C Hoffman; S L Hu; L Corey
Journal:  Lancet       Date:  1991-03-09       Impact factor: 79.321

5.  Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein.

Authors:  P W Mason; J M Dalrymple; M K Gentry; J M McCown; C H Hoke; D S Burke; M J Fournier; T L Mason
Journal:  J Gen Virol       Date:  1989-08       Impact factor: 3.891

6.  Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection.

Authors:  P W Mason; S Pincus; M J Fournier; T L Mason; R E Shope; E Paoletti
Journal:  Virology       Date:  1991-01       Impact factor: 3.616

7.  Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates.

Authors:  E Konishi; I Kurane; P W Mason; R E Shope; N Kanesa-Thasan; J J Smucny; C H Hoke; F A Ennis
Journal:  Vaccine       Date:  1998-05       Impact factor: 3.641

8.  Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes.

Authors:  M Kozak
Journal:  Cell       Date:  1986-01-31       Impact factor: 41.582

9.  Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.

Authors:  J F Rooney; C Wohlenberg; K J Cremer; B Moss; A L Notkins
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

10.  Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells.

Authors:  P W Mason
Journal:  Virology       Date:  1989-04       Impact factor: 3.616

View more
  33 in total

1.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

Review 2.  West Nile virus: a growing concern?

Authors:  L Hannah Gould; Erol Fikrig
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.

Authors:  Emmanuel Feroldi; Maria Rosario Capeding; Mark Boaz; Sophia Gailhardou; Claude Meric; Alain Bouckenooghe
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

4.  Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.

Authors:  T P Monath; I Levenbook; K Soike; Z X Zhang; M Ratterree; K Draper; A D Barrett; R Nichols; R Weltzin; J Arroyo; F Guirakhoo
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles.

Authors:  E Konishi; A Fujii; P W Mason
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model.

Authors:  Roberto S Dias; Michelle D Teixeira; Mariana F Xisto; John W O Prates; Jessica D Da Silva; Iago O Mello; Cynthia C Da Silva; Sérgio O De Paula
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

7.  Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.

Authors:  F Guirakhoo; J Arroyo; K V Pugachev; C Miller; Z X Zhang; R Weltzin; K Georgakopoulos; J Catalan; S Ocran; K Soike; M Ratterree; T P Monath
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

9.  Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines.

Authors:  Mariel E Pérez-Vélez; Teresita García-Nieves; Candimar Colón-Sánchez; Idalí Martínez
Journal:  P R Health Sci J       Date:  2009-09       Impact factor: 0.705

10.  Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine.

Authors:  Asato Kojima; Atsushi Yasuda; Hideki Asanuma; Toyokazu Ishikawa; Akihisa Takamizawa; Kotaro Yasui; Takeshi Kurata
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.